The frequency and predictability of switching biologic agents in severe asthma: A real-world perspective. [PDF]
Can A, Atik Ö.
europepmc +1 more source
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma +9 more
wiley +1 more source
Obesity: Next game changer of allergic airway diseases? [PDF]
Li W, Marx N, Yang Q, Fang D, Zhang Y.
europepmc +1 more source
Homo sapiens, industrialisation and the environmental mismatch hypothesis
ABSTRACT For the vast majority of the evolutionary history of Homo sapiens, a range of natural environments defined the parameters within which selection shaped human biology. Although human‐induced alterations to the terrestrial biosphere have been evident for over 10,000 years, the pace and scale of change has accelerated dramatically since the onset
Daniel P. Longman, Colin N. Shaw
wiley +1 more source
Immunological Status of Saliva in Children with Asthma by Disease Severity. [PDF]
Leshchuk S, Hakami Z, Vishwanathaiah S.
europepmc +1 more source
Nutraceuticals Against Oxidative Stress in Allergic Diseases. [PDF]
Di Salvo M +4 more
europepmc +1 more source
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bernardo Sousa‐Pinto +121 more
wiley +1 more source
Real-World Efficacy of Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium on Diaphragmatic Workload Assessed by Ultrasound and Lung Function in Patients with Uncontrolled Asthma. [PDF]
Maiorano A +9 more
europepmc +1 more source
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz +12 more
wiley +1 more source
Molecular profiling of exhaled breath condensate in respiratory diseases. [PDF]
Malerba M +4 more
europepmc +1 more source

